Precigen reports Q4 2022 loss of $22.2M; cash $99.7M; clinical progress in RRP and AML

PRECIGEN, INC.

Q4 loss from continuing ops $22.2M ($0.11/sh); full year loss $79.8M ($0.40/sh).
Cash, equivalents, short-term investments, restricted cash $99.7M as of Dec 31, 2022.
Divested Trans Ova Genetics for $162.3M net; retired $156.7M of convertible notes in 2022.
Jan 2023 public offering raised ~$73M net from 44M shares at $1.75/sh.
Positive Phase 1 data: PRGN-2012 in RRP (50% complete response) and PRGN-3006 in AML (27% ORR).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PRECIGEN, INC. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated March 6, 2023, reporting its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

PRECIGEN, INC. filing history →

Source: SEC EDGAR

accession 0000950103-23-003720

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.